# US 2026/0062458 A1 · Chimeric antigen receptor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0062458 A1
- Document ID: US20260062458A1
- Status: Published application
- Kind: A1
- Application number: 19/172,331
- Filed: 2025-04-07
- Published: 2026-03-05
- Earliest claimed: 2018-10-17
- Assignees: Autolus Limited
- Applicants: Autolus Limited
- Inventors: Martin Pulé; Kwee Yong; Lydia Lee; Ben Draper
- Web page: https://patentgrep.com/patent/US20260062458A1

## CPC

- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4215: {Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30}
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/02: Immunomodulators
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70575: {NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154 (NGF C07K14/48, TNF C07K14/525)}
- C07K 16/18: against material from animals or humans
- C12N 5/0646: {Natural killers cells [NK], NKT cells}
- C12N 15/85: for animal cells
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/46: characterised by the cancer treated
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides a chimeric antigen receptor (CAR) comprising: (i) a B cell maturation antigen (BCMA)-binding domain which comprises at least part of a proliferation-inducing ligand (APRIL); (ii) a spacer domain (iii) a transmembrane domain; and (iv) an intracellular T cell signaling domain. The invention also provides the use of such a T-cell expressing such a CAR in the treatment of plasma-cell mediated diseases, such as multiple myeloma.

## Claims

### Claim 1

A chimeric antigen receptor (CAR) comprising:
(i) a B cell maturation antigen (BCMA)-binding domain which comprises at least part of a proliferation-inducing ligand (APRIL),
(ii) a spacer domain,
(iii) a transmembrane domain, and
(iv) (iii) an intracellular T cell signaling domain.

### Claim 2 (depends on 1)

A CAR according to claim 1, wherein the BCMA-binding domain comprises a truncated APRIL which comprises the BCMA binding site but lacks the amino terminal portion of APRIL responsible for proteoglycan binding.

### Claim 3 (depends on 2)

A CAR according to claim 2, which comprises the sequence shown as SEQ ID No. 14 or a variant thereof having at least 80% sequence identity which binds BCMA.

### Claim 4 (depends on 1)

A CAR according to claim 1, wherein the transmembrane and intracellular T-cell signalling domain comprise the sequence shown as SEQ ID No. 7 or a variant thereof having at least 80% sequence identity.

### Claim 5 (depends on 1)

A CAR according to claim 1, wherein the spacer comprises one of the following: a human IgG1 spacer, an IgG1 hinge, or a CD8 stalk.

### Claim 6 (depends on 5)

A CAR according to claim 5, wherein the spacer comprises a CD8 stalk.

### Claim 7 (depends on 1)

A CAR according to claim 1, which comprises the sequence shown as SEQ ID No. 1, 2, 3, 4, 5 or 6 or a variant thereof which has at least 80% sequence identity but retains the capacity to i) bind BCMA and ii) induce T cell signalling.

### Claim 8 (depends on 1)

A nucleic acid sequence which encodes a CAR according to claim 1.

### Claim 9 (depends on 8)

A nucleic acid sequence according to claim 8 which comprises the sequence shown as SEQ ID No 15, 16, 17, 18, 19 or 20 or a variant thereof having at least 80% sequence identity.

### Claim 10 (depends on 8)

A vector which comprises a nucleic acid sequence according to claim 8.

### Claim 11 (depends on 1)

A T cell or NK cell which expresses a CAR according to claim 1.

### Claim 12 (depends on 11)

A method for making a T cell or NK cell according to claim 11, which comprises the step of introducing into a T cell or NK cell a nucleic acid which encodes a CAR comprising:
(i) a B cell maturation antigen (BCMA)-binding domain which comprises at least part of a proliferation-inducing ligand (APRIL),
(ii) a spacer domain,
(iii) a transmembrane domain, and
(iv) an intracellular T cell signaling domain.

### Claim 13 (depends on 10)

A pharmaceutical composition which comprises a vector according to claim 10, together with a pharmaceutically acceptable carrier, diluent or excipient.

### Claim 14 (depends on 10)

A method for treating a plasma cell disorder which comprises the step of administering a vector according to claim 10 to a subject.

### Claim 15 (depends on 14)

A method according to claim 14, wherein the plasma cell disorder is selected from plasmacytoma, plasma cell leukemia, multiple myeloma, macroglobulinemia, amyloidosis, Waldenstrom's macroglobulinemia, solitary bone plasmacytoma, extramedullary plasmacytoma, osteosclerotic myeloma, heavy chain diseases, monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.

### Claim 16 (depends on 15)

A method according to claim 15, wherein the plasma cell disorder is multiple myeloma.

### Claim at position 17

17-18. (canceled)

### Claim 19 (depends on 11)

A pharmaceutical composition which comprises a T cell/NK cell according to claim 11, together with a pharmaceutically acceptable carrier, diluent or excipient.

### Claim 20 (depends on 11)

A method for treating a plasma cell disorder which comprises the step of administering a T cell or NK cell according to claim 11 to a subject.

### Claim 21 (depends on 20)

A method according to claim 20, wherein the plasma cell disorder is selected from plasmacytoma, plasma cell leukemia, multiple myeloma, macroglobulinemia, amyloidosis, Waldenstrom's macroglobulinemia, solitary bone plasmacytoma, extramedullary plasmacytoma, osteosclerotic myeloma, heavy chain diseases, monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.

### Claim 22 (depends on 20)

A method according to claim 20, wherein the plasma cell disorder is multiple myeloma.
